tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Sykes, 74 are a HOLD (32.74%), 34 are a SELL (15.04%), 118 are a BUY (52.21%).
Analyst Matthew Sykes, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 61.02% that have a potential upside of 23.48% achieved within 126 days.
Matthew Sykes’s has documented 427 price targets and ratings displayed on 36 stocks. The coverage is on Healthcare, Basic Materials sectors.
Most recent stock forecast was given on TXG, 10X Genomics at 12-May-2025.
Analyst best performing recommendations are on ZY (ZYMERGEN).
The best stock recommendation documented was for ZY (ZYMERGEN) at 8/4/2021. The price target of $12 was fulfilled within 1 day with a profit of $3.75 (45.45%) receiving and performance score of 454.55.
Average potential price target upside
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
Since 23-Jul-2025
$240
$4.01 (1.70%)
$230
1 months 7 days ago
(15-Dec-2025)
11/15 (73.33%)
$13.67 (6.04%)
340
Buy
Since 10-Apr-2025
$250
$14.01 (5.94%)
$225
3 months ago
(22-Oct-2025)
17/25 (68%)
$31.9 (14.63%)
242
Buy
Since 04-Jan-2021
$245
$9.01 (3.82%)
$226
3 months 15 days ago
(07-Oct-2025)
5/7 (71.43%)
$36.23 (17.35%)
91
Buy
Since 13-Dec-2024
$220
$-15.99 (-6.78%)
$290
4 months ago
(22-Sep-2025)
3/4 (75%)
$29.88 (15.72%)
43
Buy
Since 03-Oct-2023
$225
$-10.99 (-4.66%)
$240
5 months 30 days ago
(23-Jul-2025)
10/16 (62.5%)
$27.46 (13.90%)
203
What Year was the first public recommendation made by Matthew Sykes?
